Ozempic and other GLP-1 litigation are still in their early stages, and no trials or settlements have been finalized
FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products What health care providers, compounders and patients should know FDA has received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products
In clinical practice focusing on prognostic indicators for ischemic stroke patients found that there was a close negative correlation between IL-10 and NIHSS scores (P=0.0006), but not between IL-4 and NIHSS scores (P=0.088) (105)
An analysis of Medicare Part D formularies for 2024 revealed a startling reality: while the original brand-name Humira enjoyed nearly universal coverage, appearing on 99% of plans, only about half of all plans covered any biosimilar alternative
Let that sink in for a moment nearly 9 out of 10 patients who had failed other treatments found relief with these medications
These plans have the highest monthly rates
